COVID-19 and financial toxicity in patients with renal cell carcinoma - Takeaways - MDSpire

COVID-19 and financial toxicity in patients with renal cell carcinoma

  • By

  • Michael D. Staehler

  • Dena J. Battle

  • Cristiane D. Bergerot

  • Sumanta Kumar Pal

  • David F. Penson

  • October 22, 2020

  • 0 min

Share

  • 1

    The COVID-19 crisis has significantly impacted cancer care, leading to changes in treatment protocols and increased financial toxicity for patients.

  • 2

    Advances in renal cell carcinoma treatment have improved outcomes, but rising cost-sharing has shifted more financial burden onto patients.

  • 3

    A survey of 539 patients revealed high levels of anxiety regarding COVID-19 and its financial implications, particularly among lower-income individuals.

  • 4

    Only 8% of patients reported satisfaction with their financial situation, with many expressing concerns about treatment costs and job security.

  • 5

    The median financial toxicity score among patients was 21.5, indicating significant financial distress, especially among those receiving systemic therapy.

Original Source(s)

COVID-19 and financial toxicity in patients with renal cell carcinoma

  • by Michael D. Staehler, Dena J. Battle, Cristiane D. Bergerot, Sumanta Kumar Pal, David F. Penson

  • October 22, 2020

Related Content

Roswell Park Set to Open Several New Trials this Year for Innovative CAR T-Cell Therapies

CAR T-cell therapies are the future of cancer treatment and Roswell Park Comprehensive Cancer Center is preparing to open a number of new trials based on research originating here and in partnership with the industry.

  • March 17, 2025

  • 2 min
Efficacy of immune checkpoint inhibitors in renal cell carcinoma venous tumour thrombus shrinkage (UroCCR 128)

Consensus Guidelines for the Management of Locally Advanced and Metastatic Renal Cell Carcinoma by the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology for 2025